Skip to main content
S&P 5007,675.02+1.10%DOW52,610.71+1.05%NASDAQ26,415.79+1.28%BTC$77,891.00+1.00%ETH$2,570.85+5.36%GOLD$4,410.70+0.08%OIL$99.47-2.94%
Smart Investors Daily
IV

OTC · IVRO

InVitro International

Healthcare · Medical - Diagnostics & Research

$0.06

Down-$0.01 (-7.83%)

Updated Sep 11, 2026, 4:08 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.26M
P/E ratio
18.64
Dividend yield
0.00%
52-week range
$0.03 – $0.16
Volume
3K
Avg. volume
12.21K

Price performance

IVRO price history

1M range · 0 trading sessions · Daily adjusted prices

IVRO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IVRO news

The latest Smart Investors Daily articles mentioning IVRO.

Stock researchCompany · Overview

IVRO research

Overview

Company profile and research snapshot.

Company profile

INVITRO INTL

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Dec 9, 2025

Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains

Placentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of $878,937, up 8.3% over FY '24. Net income of $121,980 advanced 14.3% for the same period. CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the world announced they have already, or will soon, cease funding for animal testing; some have stopped now. Further, some RA's state OECD validated NON-animal.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By